目的观察保肺康治疗气阴两虚、痰瘀阻络型慢性阻塞性肺疾病合并肺间质纤维化(chronic obstructive pulmonary disease with pulmonary interstitial fibrosis,COPD-PIF)患者的临床疗效。方法将符合纳入标准的COPD-PIF患者按照随机数字...目的观察保肺康治疗气阴两虚、痰瘀阻络型慢性阻塞性肺疾病合并肺间质纤维化(chronic obstructive pulmonary disease with pulmonary interstitial fibrosis,COPD-PIF)患者的临床疗效。方法将符合纳入标准的COPD-PIF患者按照随机数字表法分为2组,治疗组予以中药保肺康联合西医综合治疗,对照组予以中药安慰剂联合西医综合治疗,疗程共3个月。观察并比较2组患者治疗有效率,以及治疗前后中医证候积分、肺功能、动脉血氧分压(partial pressure of oxygen in arterial blood,PaO_(2))、慢阻肺患者自我评估测试(COPD assessment test,CAT)评分、改良英国医学研究学会(modified British medical research council,mMRC)呼吸困难指数评分、急性加重次数等指标的变化。结果治疗组患者中医证候总积分、主要症状积分、第1秒用力呼气容积(forced expiratory volume in one second,FEV1)占预计值百分比(FEV1%pred)、PaO_(2)、CAT评分、mMRC评分、急性加重次数较治疗前均有改善(P<0.05),且疗效优于对照组。相关性分析显示中医证候积分的改善与CAT评分、mMRC评分呈显著正相关,与FEV1%pred、肺一氧化碳弥散量(diffusing capacity of the lung for carbon monoxide,DLCO)占预计值百分比(DLCO%pred)呈显著负相关。结论中药保肺康不仅可以显著改善COPD-PIF患者的主要症状(喘息、胸闷、气短、咳嗽、咯痰、乏力),且能降低CAT评分、mMRC评分,改善患者氧合与肺功能,减少急性加重次数,临床疗效显著,且未见明显不良反应,值得临床推广应用。展开更多
Objective:This paper aims to determine the reliability and validity of the Chinese version of a tool that assesses the quality of life in idiopathic pulmonary fibrosis(cATAQ-IPF)in patients with interstitial lung dise...Objective:This paper aims to determine the reliability and validity of the Chinese version of a tool that assesses the quality of life in idiopathic pulmonary fibrosis(cATAQ-IPF)in patients with interstitial lung disease(ILD).Methods:We used the process of scale introduction to establish cATAQ-IPF.The content validity of the scale was evaluated by six experts.A total of 92 patients with ILD completed the cATAQ-IPF,St.George's respiratory questionnaire(SGRQ),and The Medical Research Council dyspnoea scale at the baseline,and 15 patients completed cATAQ-IPF at the follow-up period 2 weeks later.Thus,yielding data were used to assess various psychometric properties of cATAQ-IPE Intraclass correlation coefficient(ICC),Cronbach'sαcoefficient,content validity index(CVI),item-level CVI(I-CVI),Pearson's coefficients,criterion-relation validity,and known-group validity were used for data analysis.Results:The cATAQ-IPF showed excellent test-retest reliability(ICC=0.95),except for the therapy domain(Cronbach'sα=0.60)and acceptable internal consistency(Cronbach'sα=0.96 for the total).The scale-level CVI was 0.80,and the I-CVI was in the range of 0.78-1.00.The total cATAQ-IPF score was strongly correlated with the SGRQ total score(r=0.71,P<0.01).The cATAQ-IPF score of patients with ILD was 250.74±47.39,and that of patients with IPF was 287.90±22.56.Patients with IPF possessed considerable impairments in health-related quality of life according to the cATAQ-IPF score(t=4.94,P<0.01).Conclusions:The cATAQ-IPF is a reliable and valid instrument for the evaluation of quality of life of Chinese patients with various forms of ILD.展开更多
文摘目的观察保肺康治疗气阴两虚、痰瘀阻络型慢性阻塞性肺疾病合并肺间质纤维化(chronic obstructive pulmonary disease with pulmonary interstitial fibrosis,COPD-PIF)患者的临床疗效。方法将符合纳入标准的COPD-PIF患者按照随机数字表法分为2组,治疗组予以中药保肺康联合西医综合治疗,对照组予以中药安慰剂联合西医综合治疗,疗程共3个月。观察并比较2组患者治疗有效率,以及治疗前后中医证候积分、肺功能、动脉血氧分压(partial pressure of oxygen in arterial blood,PaO_(2))、慢阻肺患者自我评估测试(COPD assessment test,CAT)评分、改良英国医学研究学会(modified British medical research council,mMRC)呼吸困难指数评分、急性加重次数等指标的变化。结果治疗组患者中医证候总积分、主要症状积分、第1秒用力呼气容积(forced expiratory volume in one second,FEV1)占预计值百分比(FEV1%pred)、PaO_(2)、CAT评分、mMRC评分、急性加重次数较治疗前均有改善(P<0.05),且疗效优于对照组。相关性分析显示中医证候积分的改善与CAT评分、mMRC评分呈显著正相关,与FEV1%pred、肺一氧化碳弥散量(diffusing capacity of the lung for carbon monoxide,DLCO)占预计值百分比(DLCO%pred)呈显著负相关。结论中药保肺康不仅可以显著改善COPD-PIF患者的主要症状(喘息、胸闷、气短、咳嗽、咯痰、乏力),且能降低CAT评分、mMRC评分,改善患者氧合与肺功能,减少急性加重次数,临床疗效显著,且未见明显不良反应,值得临床推广应用。
基金The authors are grateful for financial support from the China Medical Board(NO.10-020-201211)
文摘Objective:This paper aims to determine the reliability and validity of the Chinese version of a tool that assesses the quality of life in idiopathic pulmonary fibrosis(cATAQ-IPF)in patients with interstitial lung disease(ILD).Methods:We used the process of scale introduction to establish cATAQ-IPF.The content validity of the scale was evaluated by six experts.A total of 92 patients with ILD completed the cATAQ-IPF,St.George's respiratory questionnaire(SGRQ),and The Medical Research Council dyspnoea scale at the baseline,and 15 patients completed cATAQ-IPF at the follow-up period 2 weeks later.Thus,yielding data were used to assess various psychometric properties of cATAQ-IPE Intraclass correlation coefficient(ICC),Cronbach'sαcoefficient,content validity index(CVI),item-level CVI(I-CVI),Pearson's coefficients,criterion-relation validity,and known-group validity were used for data analysis.Results:The cATAQ-IPF showed excellent test-retest reliability(ICC=0.95),except for the therapy domain(Cronbach'sα=0.60)and acceptable internal consistency(Cronbach'sα=0.96 for the total).The scale-level CVI was 0.80,and the I-CVI was in the range of 0.78-1.00.The total cATAQ-IPF score was strongly correlated with the SGRQ total score(r=0.71,P<0.01).The cATAQ-IPF score of patients with ILD was 250.74±47.39,and that of patients with IPF was 287.90±22.56.Patients with IPF possessed considerable impairments in health-related quality of life according to the cATAQ-IPF score(t=4.94,P<0.01).Conclusions:The cATAQ-IPF is a reliable and valid instrument for the evaluation of quality of life of Chinese patients with various forms of ILD.
